Long-term (5-year) antibody persistence following two- and three-dose regimens of a combined hepatitis A and B vaccine in children aged 1-11 years.
This study compared the long-term persistence of anti-hepatitis A (anti-HAV) and B (anti-HBs) antibodies, 5 years after vaccination of subjects aged 1-11 years with a combined hepatitis A and B vaccine either in a two-dose (0, 6 months, Adult formulation) or a three-dose (0, 1, 6 months, Paediatric formulation) schedule. At the end of the 5 years, all subjects (100%) in both groups continued to have anti-HAV antibodies > or =15mIU/mL, while 94-97% of subjects in both groups had anti-HBs antibody concentrations > or =10mIU/mL. Subjects with anti-HBs antibody concentration < or =10mIU/mL were administered a challenge dose of hepatitis B vaccine. All subjects mounted a vigorous immune response to the challenge indicating the presence of immunological memory to HBV.
Marshall
Helen
H
University of Adelaide, Adelaide, South Australia, Australia. helen.marshall@adelaide.edu.au
Nolan
Terry
T
Díez Domingo
Javier
J
Rombo
Lars
L
Sokal
Etienne M
EM
Marès
Josep
J
Casanovas
Josep M
JM
Kuriyakose
Sherine
S
Leyssen
Maarten
M
Jacquet
Jeanne-Marie
JM
D002648:Child; D002675:Child, Preschool; D005260:Female; D022362:Hepatitis A Vaccines / Q000008:administration & dosage / Q000276:immunology*; D006510:Hepatitis B Antibodies / Q000097:blood* / Q000276:immunology; D017325:Hepatitis B Vaccines / Q000008:administration & dosage / Q000276:immunology*; D006801:Humans; D007223:Infant; D008297:Male; D017778:Vaccines, Combined / Q000276:immunology*
D022362:Hepatitis A Vaccines; D006510:Hepatitis B Antibodies; D017325:Hepatitis B Vaccines; D017778:Vaccines, Combined